Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indane-5-sulfonamide is a small molecule sulfonamide compound characterized by an indane (bicyclic benzene-cyclopentane) core with a sulfonamide group at the 5-position. It acts as an inhibitor of carbonic anhydrase enzymes, particularly human isoforms II and XII. Carbonic anhydrases catalyze the reversible hydration of carbon dioxide and are involved in physiological processes such as pH regulation and fluid balance. Indane-5-sulfonamide has demonstrated potent inhibitory activity against these enzymes (Ki values in the low nanomolar range), making it a useful scaffold for developing anticonvulsant agents and potential anticancer or antidiabetic drugs. However, it is considered experimental and not approved for clinical use[1][3][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indane-5-sulfonamide.